Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.

Eric Lawitz,Mark Sulkowski,Ira Jacobson,Walter K Kraft,Benedict Maliakkal,Mohamed Al-Ibrahim,Stuart C Gordon,Paul Kwo,Juergen Kurt Rockstroh,Paul Panorchan,Michelle Miller,Luzelena Caro,Richard Barnard,Peggy May Hwang,Jacqueline Gress,Erin Quirk,Niloufar Mobashery

Antiviral Research（2013）

引用 29|浏览15

暂无评分

摘要

•A placebo-controlled dose-ranging phase 1b study of vaniprevir monotherapy.•Forty adult patients with genotype 1 chronic hepatitis C virus infection.•Mean drop in HCV RNA of 1.8–4.6log10IU/ml after 1week of treatment.•Most commonly reported drug-related AEs were diarrhea (n=5) and nausea (n=5).•Further development of vaniprevir is ongoing.

查看译文

关键词

AE,AUC,bid,BMI,BUN,CI,Cmax,Ctrough,CRU,DAA,EC50,ECG,GMR,GT,HCV,IC50,IRF-3,LLoQ,MRL,NS3/4A,PCR,PD,PEG-IFN,PI,PK,qd,RAVs,RBV,SAE,SEAP,SVR,t1/2,Tmax,ULN

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要